SOURCE: Salient Surgical Technologies
June 17, 2010 08:42 ET
Salient Opens European Headquarters to Support Expansion Efforts Driven by Success of Its AQUAMANTYS® System
Targeting of Orthopedic Reconstruction and Spine Procedures to Power Growth in Established Markets
PORTSMOUTH, NH--(Marketwire - June 17, 2010) - Salient Surgical Technologies, Inc. has opened an office in Amsterdam, the Netherlands to support its global expansion efforts. Salient first entered the European market in 2001 with its line of monopolar sealers for use in solid organ resections. Clinical results in total joint replacement and spine procedures with the AQUAMANTYS® System, a bipolar technology, have led to rapid growth and a renewed focus on expanding the company's presence in international markets.
Combined, the five largest markets in Europe (UK, Germany, France, Italy and Spain) perform over one million orthopedic reconstruction procedures annually.
"TRANSCOLLATION™ technology is a natural fit for all healthcare systems that seek to improve outcomes and lower costs," said Salient president and CEO Joseph F. Army in a statement. "Our goal is to make the AQUAMANTYS System the global standard of care for reducing the clinical and economic burdens associated with bleeding and blood loss during surgical procedures."
The new European office will house Salient's international sales and marketing team.
About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology delivers concurrent radiofrequency energy and saline for haemostatic sealing of soft tissue and bone at the operative site. Salient's products are currently used in orthopedic reconstruction and trauma, spine surgery and surgical oncology. To date, TRANSCOLLATION technology has been used in over 400,000 surgical procedures.